ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Korea Otsuka International Asia Arab
ClinicalTrials.gov Identifier:
NCT00484471
First received: June 8, 2007
Last updated: November 27, 2012
Last verified: November 2012
  Purpose

To compare combination treatment of aripiprazole plus valproate versus valproate alone in the prevention of relapse in bipolar I disorder patients with symptomatic remission after 5-6 weeks open-label acute treatment with aripiprazole plus valproate for manic or mixed episode, with or without psychotic features.


Condition Intervention Phase
Bipolar Disorder
Drug: aripiprazole
Drug: valproate
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder

Resource links provided by NLM:


Further study details as provided by Korea Otsuka International Asia Arab:

Primary Outcome Measures:
  • Time to relapse in double-blind treatment phase [ Time Frame: throughout the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean change from baseline to all time point in YMRS total score; [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
  • Mean change from baseline to all time points in MADRS total score [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
  • Response rate (≥ 50% improvement in YMRS total score) at all time points [ Time Frame: throughout the study ] [ Designated as safety issue: No ]

Enrollment: 127
Study Start Date: October 2007
Study Completion Date: November 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: aripiprazole
15-30 mg/day aripiprazole, 22 weeks
Other Name: Abilify
Drug: valproate
sufficient dose as determined by investigator to maintain the therapeutic level.
Placebo Comparator: 2 Drug: valproate
sufficient dose as determined by investigator to maintain the therapeutic level.
Drug: placebo
placebo to aripiprazole, 22 weeks

Detailed Description:

Further study details as provided by Korea OIAA

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects able to give informed consent, and/or consent obtained from a legally acceptable representative (as required by IRB/IEC) prior to the initiation of any protocol required procedures;
  2. Subjects with Bipolar I Disorder, manic or mixed episode, with or without psychotic features, as defined by DSM-IV-TR and confirmed by the M.I.N.I.;
  3. Subjects who are able to understand the nature of the study and follow protocol requirements including the prescribed dosage regimens, capsule/tablet ingestion, discontinuation of prohibited concomitant medications, and who can be reliably rated on assessment scales;
  4. Subjects willing to discontinue all medication starting from the signing of the informed consent and during the study phases (allowed exceptions noted in Section 6.4.2);
  5. Men or women aged ≥ 18 and ≤ 65 years;
  6. Subjects with YMRS total score ≥ 20 (to be assessed prior entry into open-label acute treatment phase);
  7. YMRS total score ≤ 12 for 2 consecutive visits (to be assessed at Week 5 and/or Week6 prior entry into double-blind treatment phase).

Exclusion Criteria:

  1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to four weeks after completion of the study. Acceptable methods include oral, injectable or implanted contraceptives, intrauterine devices or barrier methods such as condoms, diaphragm, and spermicides;
  2. Women who are pregnant or breast-feeding;
  3. Subjects presenting clinically with a current DSM-IV-TR diagnosis of delirium, dementia, amnestic or other cognitive disorders, or a psychotic disorder (e.g., schizophrenia or schizoaffective disorder). Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder;
  4. Subjects with a current Axis I (DSM-IV-TR) diagnosis of Bipolar II Disorder, rapid cyclers (experiencing four or more manic or depressive episodes per year), Bipolar Disorder NOS, or any other primary psychiatric disorder other than Bipolar I Disorder;
  5. Subjects with documented evidence of first manic episode;
  6. Subjects considered treatment refractory for manic symptoms; (Note: if a subject has failed ≥ 2 antimanic treatments, e.g., antipsychotic, lithium, valproate or carbamazepine at therapeutic dose and duration, exclusive of the current episode, obtain permission from the Otsuka medical monitor to include the subject)
  7. Subjects previously nonresponsive to aripiprazole for manic symptoms;
  8. Subjects with a significant risk of committing suicide based on history, mental status exam, or investigator's judgment;
  9. Subjects who have met DSM-IV-TR criteria for substance abuse within the past three months, or substance dependence* within the past 6 months, including benzodiazepines; (* exceptional for subjects with substance dependence on nicotine or caffeine);
  10. Subjects with thyroid pathology (e.g., hypothyroidism or hyperthyroidism) unless condition has been stabilized with medications for at least the past three months; (Note: Subjects with an abnormal thyroid function test may be retested prior to the start of study medication. Subjects with an abnormal thyroid function test at screening will not be eligible for the study, unless permission is obtained from Otsuka);
  11. Subjects who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine (e.g., Addison's Disease), immune, neurologic, or hematologic disease as determined by the clinical judgment of the investigator;
  12. Subjects with a significant history of seizure disorder (e.g., epilepsy);
  13. The following laboratory tests results, vital signs, and ECG findings are exclusionary:

    • Platelets ≤ 75000/mm3
    • Hemoglobin ≤ 9g/dL
    • Neutrophils, absolute ≤ 1000/ mm3
    • SGOT (AST) > 3x Upper Limit of Normal
    • SGPT (ALT) > 3x Upper Limit of Normal
    • Creatinine ≥ 2 mg/dL
    • QTc > 475 msec
  14. Subjects with a recent antipsychotic use who have a CPK ≥ 550 IU (Otsuka should be contacted to discuss any elevated CPK levels);
  15. Subjects who are known to be allergic, intolerant, or unresponsive to valproate or to aripiprazole;
  16. Subjects with a history of neuroleptic malignant syndrome from antipsychotic agents;
  17. Subjects likely to require prohibited concomitant therapy during the study as indicated in Section 6.4 of the protocol;
  18. Recent treatment of their most recent manic or mixed acute episode with a long acting antipsychotic in which the last dose was less than one full cycle plus one week prior to entering Phase 2 (haloperidol decanoate treatment within the past five weeks, fluphenazine decanoate treatment within the past three weeks or Risperdal ConstaTM treatment within the past three weeks);
  19. Subjects likely to require the initiation of intensive individual psychotherapy during the course of the study (Note: Group and supportive therapy is allowed, if part of the subject's ongoing treatment. Individual psychotherapy is allowed if the subject has consistently received psychotherapy for at least 3 months prior to the study and will continue during the study);
  20. ECT treatment within the current episode or within two months prior to the study;
  21. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00484471

Locations
Hong Kong
Castle Peak Hospital
Tuen Mun, Hong Kong
Philippines
National Center for Mental Health
Mandaluyong, Philippines
Philippine General Hospital
Manilla, Philippines
University of Sto. Tomas Hospital
Manilla, Philippines
Veterans Medical Memorial Center
Quezon, Philippines
Taiwan
Changhua Chrisitian Hospital
Changhua, Taiwan
Tsao-Tun Psychiatric Center
Nantou, Taiwan
National Cheng-Kung University Hospital
Tainan, Taiwan
Jia-Nan Mental Hospital
Tainan, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Taoyuan Mental Hospital
Taoyuan, Taiwan
Thailand
Somdej Chaophraya Hospital
Bangkok, Thailand
Siriraj Hospital
Bangkok, Thailand
Sponsors and Collaborators
Korea Otsuka International Asia Arab
Investigators
Study Chair: Nan-Ying Chiu, MD Changhua Christian Hospital, Taiwan
Principal Investigator: Hun-Yu Chang, MD Taoyuan Mental Hospital
Principal Investigator: Yen-Kung Yang, MD National Cheng-Kung University Hospital
Principal Investigator: Wen-Chen Ouyang, MD Jia-Nan Mental Hospital
Principal Investigator: Wei-Wen Lin, MD Tri-Service General Hospital
Principal Investigator: Tso-Ren Wang, MD Tsao-Tun Psychistric Center
Principal Investigator: Efren Reyes, MD National Center for Mental Health (NCMH)
Principal Investigator: Rosanna de Guzman, MD Philippine General Hospital (PGH)
Principal Investigator: Gabino Ranoa, MD University of Sto. Tomas Hospital (USTH)
Principal Investigator: Amadeo Alinea Veterans Medical Memorial Center (VMMC)
Principal Investigator: .Vasu Chantarasak, MD Somdej Chaophraya Hospital
Principal Investigator: Suttiporn Janenawasin, MD Siriraj Hospital
Principal Investigator: F K Tsang, MD Castle Peak Hospital
  More Information

No publications provided

Responsible Party: Korea Otsuka International Asia Arab
ClinicalTrials.gov Identifier: NCT00484471     History of Changes
Other Study ID Numbers: 031-OTB-0701
Study First Received: June 8, 2007
Last Updated: November 27, 2012
Health Authority: Taiwan: Institutional Review Board
Philippines: Ethics Committee
Thailand: Ethical Committee
Hong Kong: Ethics Committee

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Valproic Acid
Aripiprazole
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Antipsychotic Agents

ClinicalTrials.gov processed this record on August 25, 2014